Published in Am J Pathol on May 01, 2002
Harmful molecular mechanisms in sepsis. Nat Rev Immunol (2008) 6.03
The enigma of sepsis. J Clin Invest (2003) 4.32
The role of the anaphylatoxins in health and disease. Mol Immunol (2009) 2.95
Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 2.12
C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol (2008) 1.92
Interactions between coagulation and complement--their role in inflammation. Semin Immunopathol (2011) 1.46
New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med (2010) 1.37
Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol (2012) 1.34
The harmful role of c5a on innate immunity in sepsis. J Innate Immun (2010) 1.31
Functions of the complement components C3 and C5 during sepsis. FASEB J (2008) 1.30
An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med (2005) 1.29
Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. Crit Care (2009) 1.20
Molecular events in the cardiomyopathy of sepsis. Mol Med (2008) 1.18
Bench-to-bedside review: Beta-adrenergic modulation in sepsis. Crit Care (2009) 1.18
Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology (2010) 1.10
Molecular mechanisms of inflammation and tissue injury after major trauma--is complement the "bad guy"? J Biomed Sci (2011) 1.04
The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis. PLoS One (2008) 1.03
Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) (2009) 1.03
Sepsis, apoptosis and complement. Biochem Pharmacol (2008) 1.01
Complement activation in emergency department patients with severe sepsis. Acad Emerg Med (2010) 0.94
Inflammatory response in microvascular endothelium in sepsis: role of oxidants. J Clin Biochem Nutr (2008) 0.92
Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. Transl Res (2015) 0.90
A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis. Mol Ther (2013) 0.85
Role of complement in multiorgan failure. Clin Dev Immunol (2012) 0.83
Complement, thrombotic microangiopathy and disseminated intravascular coagulation. J Intensive Care (2014) 0.80
Complement C5 and early oxygen kinetics during murine sepsis. Acad Emerg Med (2005) 0.79
New insights for C5a and C5a receptors in sepsis. Front Immunol (2012) 0.79
Hemostatic properties of a venomic protein in rat organ trauma. Exp Mol Pathol (2009) 0.78
Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage. Clin Exp Immunol (2003) 0.78
Diagnostic value of plasminogen activity level in acute mesenteric ischemia. World J Gastroenterol (2008) 0.77
Histopathologic insights into the mechanism of anti-non-Gal antibody-mediated pig cardiac xenograft rejection. Xenotransplantation (2014) 0.76
Complement and sepsis-induced heart dysfunction. Mol Immunol (2016) 0.75
Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490. J Inflamm (Lond) (2009) 0.75
Assessment of interleukin-17A, C5a and RANTES for early diagnosis of neonatal sepsis - a preliminary study. Cent Eur J Immunol (2017) 0.75
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
The effects of bacterial endotoxins on host mediation systems. A review. Am J Pathol (1978) 6.03
Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med (1984) 5.89
Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg (1992) 4.50
Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol (1977) 4.35
Animal models of sepsis and shock: a review and lessons learned. Shock (1998) 3.65
Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest (1983) 3.47
Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome) JAMA (1993) 2.88
Protective effects of C5a blockade in sepsis. Nat Med (1999) 2.50
Regulation of blood coagulation. Biochim Biophys Acta (2000) 1.97
Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem (1988) 1.88
Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA (1993) 1.88
Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest (1987) 1.74
Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest (1986) 1.71
Serum complement levels in bacteremia due to gram-negative organisms. N Engl J Med (1973) 1.70
C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med (1988) 1.67
C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest (1979) 1.63
Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome. Crit Care Med (1997) 1.60
Role of C5a in multiorgan failure during sepsis. J Immunol (2001) 1.53
Heparin cofactor activity measured with an amidolytic method. Thromb Res (1975) 1.42
A comparison of immunologic profiles and their influence on bacteremia in surgical patients with a high risk of infection. Surgery (1979) 1.41
Role of coagulation inhibitors in inflammation. Thromb Haemost (2001) 1.40
Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors. J Exp Med (1982) 1.35
C5a induces tissue factor activity on endothelial cells. Thromb Haemost (1997) 1.34
Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med (1989) 1.34
Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood (1994) 1.28
C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes. Am J Pathol (1987) 1.18
Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost (1996) 1.18
C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol (1990) 1.16
Chronological changes in the complement system in sepsis. Surg Today (1996) 1.14
Characterization of the murine plasma fibrinolytic system. Eur J Biochem (1994) 1.14
Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. Surgery (1981) 1.12
Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost (1991) 1.11
Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol (1998) 1.03
Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol (1998) 0.95
The role of plasma proteases in septic shock. N Engl J Med (1989) 0.94
Activation of the coagulation mechanism on tumor necrosis factor-stimulated cultured endothelial cells and their extracellular matrix. The role of flow and factor IX/IXa. J Biol Chem (1991) 0.93
Hemostatic/fibrinolytic protein changes in C3H/HeN mice infected with Rickettsia conorii--a model for Rocky Mountain spotted fever. Thromb Haemost (2001) 0.87
Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood (1990) 0.87
Studies on the inflammatory-coagulant axis in the baboon response to E. coli: regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor. Prog Clin Biol Res (1994) 0.86
Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Thromb Res (1995) 0.82
Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost (1998) 0.80
The effect of antithrombin on the systemic inflammatory response in disseminated intravascular coagulation. Blood Coagul Fibrinolysis (1998) 0.79
Anticytokine strategies for the treatment of septic shock: relevance of animal models. Curr Top Microbiol Immunol (1996) 0.77
Inhibition of tissue factor and cytokine release. Haemostasis (1996) 0.77
Inhibition of extrinsic coagulation activation in endotoxemia; therapeutic implications. Prog Clin Biol Res (1994) 0.77
Induced chronic intravascular coagulation in dogs. Bibl Haematol (1977) 0.77
Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc (2009) 6.71
Harmful molecular mechanisms in sepsis. Nat Rev Immunol (2008) 6.03
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
Novel strategies for the treatment of sepsis. Nat Med (2003) 5.14
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
Role of C5a in inflammatory responses. Annu Rev Immunol (2005) 4.38
The enigma of sepsis. J Clin Invest (2003) 4.32
Functional roles for C5a receptors in sepsis. Nat Med (2008) 3.33
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol (2006) 3.11
Adverse functions of IL-17A in experimental sepsis. FASEB J (2008) 2.60
Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature (2007) 2.56
Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med (2013) 2.17
Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 2.12
Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem (2007) 2.10
Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol (2003) 2.00
Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood (2011) 1.86
The complement system. Cell Tissue Res (2010) 1.86
Increased C5a receptor expression in sepsis. J Clin Invest (2002) 1.79
Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA. J Biol Chem (2006) 1.75
Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. Blood (2010) 1.73
Generation of C5a by phagocytic cells. Am J Pathol (2002) 1.72
Role of oxidants in lung injury during sepsis. Antioxid Redox Signal (2007) 1.71
Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis. Crit Care Med (2012) 1.71
Cardiac and metabolic effects of hypothermia and inhaled hydrogen sulfide in anesthetized and ventilated mice. Crit Care Med (2010) 1.70
Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem (2002) 1.67
Interaction between the coagulation and complement system. Adv Exp Med Biol (2008) 1.65
Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J Clin Invest (2009) 1.63
Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. J Immunol (2013) 1.57
Complement activation and the resulting placental vascular insufficiency drives fetal growth restriction associated with placental malaria. Cell Host Microbe (2013) 1.57
Prolylcarboxypeptidase promotes angiogenesis and vascular repair. Blood (2013) 1.54
Regulation by C5a of neutrophil activation during sepsis. Immunity (2003) 1.54
Evidence for a functional role of the second C5a receptor C5L2. FASEB J (2005) 1.53
Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol (2002) 1.53
Role of nitric oxide in acute lung inflammation: lessons learned from the inducible nitric oxide synthase knockout mouse. Crit Care Med (2002) 1.51
Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood (2007) 1.48
Evaluation of endotoxin models for the study of sepsis. Shock (2005) 1.47
Interactions between coagulation and complement--their role in inflammation. Semin Immunopathol (2011) 1.46
Complement-induced impairment of innate immunity during sepsis. J Immunol (2002) 1.44
Protection of innate immunity by C5aR antagonist in septic mice. FASEB J (2002) 1.44
Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am J Pathol (2004) 1.42
Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J (2003) 1.42
Regulatory effects of iNOS on acute lung inflammatory responses in mice. Am J Pathol (2003) 1.42
Harmful and protective roles of neutrophils in sepsis. Shock (2005) 1.41
Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood (2011) 1.39
C5 deficiency and C5a or C5aR blockade protects against cerebral malaria. J Exp Med (2008) 1.38
Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood (2004) 1.37
New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med (2010) 1.37
In vivo roles of factor XII. Blood (2012) 1.37
Humanizing the mouse: in defense of murine models of critical illness. Am J Respir Crit Care Med (2013) 1.36
Mediators and regulation of neutrophil accumulation in inflammatory responses in lung: insights from the IgG immune complex model. Free Radic Biol Med (2002) 1.35
The inflammatory response in sepsis. Trends Immunol (2012) 1.34
C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol (2004) 1.34
Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol (2012) 1.34
Relationship of acute lung inflammatory injury to Fas/FasL system. Am J Pathol (2005) 1.33
Regulatory effects of estrogen on acute lung inflammation in mice. Am J Physiol Cell Physiol (2005) 1.32
C5a receptor and thymocyte apoptosis in sepsis. FASEB J (2002) 1.31
Anti-inflammatory effects of β2 adrenergic receptor agonists in experimental acute lung injury. FASEB J (2012) 1.31
Functions of the complement components C3 and C5 during sepsis. FASEB J (2008) 1.30
An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med (2005) 1.29